Breast Cancer Clinical Trial

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Summary

This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides.

The study will be performed in two different parts. Part 1 is the Dose Escalation phase and Part 2 is the Dose Expansion phase.

The purpose of this study is to characterize the safety profile of TTI-621 and to determine the optimal dose and delivery schedule of TTI-621. In addition, the safety and antitumor activity of TTI-621 will be evaluated in combination with other anti-cancer agents or radiation.

View Full Description

Full Description

This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in patients that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides.

TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory "do not eat" (antiphagocytic) signal to macrophages.

The study will be performed in two different parts: Dose Escalation and Dose Expansion.

During the escalation part of the study, TTI-621 was studied at 3 different dose levels and at different dosing frequencies to characterize safety, tolerability, pharmacokinetics, and to determine the maximum tolerated dose (MTD).

During the expansion part of the study, TTI-621 will be studied in an expanded group of patients at the maximum feasible dosing regimen determined in the escalation phase. After completion of their initial assigned therapy, subjects may receive continuation with TTI-621. The expansion phase will further define safety and characterize efficacy of TTI-621 alone and in combination with other anti-cancer therapies.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically documented, injectable cancer lesion (limited to solid tumors and mycosis fungoides)
Adequate renal function
Adequate coagulation function
Adequate hepatic function
Disease that has progressed on standard therapy or for whom there is no other therapy option available

Exclusion Criteria:

Central nervous system involvement
Significant cardiovascular disease
Active autoimmune disease
Active hepatitis B or C or a history of HIV infection
Uncontrolled infection
History of hemolytic anemia or bleeding diathesis

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

56

Study ID:

NCT02890368

Recruitment Status:

Terminated

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

City of Hope National Medical Center
Duarte California, 91010, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York New York, 10016, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
Oregon Health & Science University
Portland Oregon, 97239, United States
University of Pittsburgh Medical Center
Pittsburgh Pennsylvania, 15237, United States
Inova Schar Cancer Institute
Fairfax Virginia, 22031, United States
University of Washington - Seattle Cancer Care Alliance
Seattle Washington, 98109, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

56

Study ID:

NCT02890368

Recruitment Status:

Terminated

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.